Effects of fibrates in kidney disease: A systematic review and meta-analysis

Journal of the American College of Cardiology

Volumn 60, Issue 20, 2012, Pages 2061-2071

  Jun, Min ^a   Zhu, Bin ^b   Tonelli, Marcello ^c   Jardine, Meg J ^a   Patel, Anushka ^a   Neal, Bruce ^a   Liyanage, Thaminda ^d   Keech, Anthony ^a   Cass, Alan ^a   Perkovic, Vlado ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF ALBERTA   (Canada)

^d ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

chronic kidney disease; fibrate; meta analysis; systematic review; triglyceride cholesterol

Indexed keywords

BEZAFIBRATE; CREATININE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FISH OIL; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

ALBUMINURIA; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEPRESSION; DIABETES MELLITUS; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; EPIGASTRIC PAIN; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; GOUT; HUMAN; KIDNEY FAILURE; LEG CRAMP; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS; MORTALITY; NAUSEA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK REDUCTION; SKIN CANCER; SYSTEMATIC REVIEW; TONSILLITIS; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84868533549     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2012.07.049     Document Type: Article

References (52)

1. S.J. Chadban, E.M. Briganti, P.G. Kerr Prevalence of kidney damage in Australian adults: the AusDiab kidney study J Am Soc Nephrol 14 2003 S131 S138
2. J. Coresh, B.C. Astor, T. Greene Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey Am J Kidney Dis 41 2003 1 12
3. S.L. White, K.R. Polkinghorne, R.C. Atkins Comparison of the prevalence and mortality risk of CKD in Australia using the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) Study GFR estimating equations: the AusDiab (Australian Diabetes, Obesity and Lifestyle) Study Am J Kidney Dis 55 2010 660 670
4. Kidney Disease Outcomes Quality Initiative (K/DOQI) Group K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification Am J Kidney Dis 39 2002 S1 S266
5. N.D. Vaziri Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences Am J Physiol Renal Physiol 290 2006 F262 F272
6. H. Abboud, W.L. Henrich Clinical practice Stage IV chronic kidney disease N Engl J Med 362 2010 56 65
7. D. Rucker, M. Tonelli Cardiovascular risk and management in chronic kidney disease Nat Rev Nephrol 5 2009 287 296
8. C.S. Fox, M.G. Larson, E.P. Leip Predictors of new-onset kidney disease in a community-based population JAMA 291 2004 844 850
9. M. Tozawa, K. Iseki, C. Iseki Influence of smoking and obesity on the development of proteinuria Kidney Int 62 2002 956 962
10. P. Muntner, J. Coresh, J.C. Smith Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study Kidney Int 58 2000 293 301
11. P.L. Drury, R. Ting, D. Zannino Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study Diabetologia 54 2011 32 43
12. M. Tonelli, N. Wiebe, B. Culleton Chronic kidney disease and mortality risk: a systematic review J Am Soc Nephrol 17 2006 2034 2047
13. Roberts M, Polkinghorne K, McDonald S, et al. Chapter 12: Cardiovascular mortality in patients who commence dialysis without clinical evidence of cardiovascular disease. ANZDATA Registry 2007 Annual Report. Australia and New Zealand Dialysis and Transplant Registry, Adelaide, South Australia.
14. C. Baigent, M.J. Landray, C. Reith The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial Lancet 377 2011 2181 2192
15. M.J. Jardine, T. Ninomiya, V. Perkovic Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial J Am Coll Cardiol 56 2010 956 965
16. Progress Collaborative Group Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack Lancet 358 2001 1033 1041
17. S. Yusuf, P. Sleight, J. Pogue The Heart Outcomes Prevention Evaluation Study Investigators Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients N Engl J Med 342 2000 145 153
18. B.E. de Galan, V. Perkovic, T. Ninomiya Lowering blood pressure reduces renal events in type 2 diabetes J Am Soc Nephrol 20 2009 883 892
19. M. Jun, C. Foote, J. Lv Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis Lancet 375 2010 1875 1884
20. E.S. Schaeffner, T. Kurth, G.C. Curhan Cholesterol and the risk of renal dysfunction in apparently healthy men J Am Soc Nephrol 14 2003 2084 2091
21. M. Manttari, E. Tiula, T. Alikoski Effects of hypertension and dyslipidemia on the decline in renal function Hypertension 26 1995 670 675
22. C. Hottelart, N. El Esper, F. Rose Fenofibrate increases creatininemia by increasing metabolic production of creatinine Nephron 92 2002 536 541
23. W.V. Brown Expert commentary: the safety of fibrates in lipid-lowering therapy Am J Cardiol 99 2007 S19 S21
24. T.M.E. Davis, R. Ting, J.D. Best Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Diabetologia 54 2011 280 290
25. M. Tonelli, D. Collins, S. Robins Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease Am J Kidney Dis 44 2004 832 839
26. A.R. Jadad, D. Carroll, A. Moore Developing a database of published reports of randomised clinical trials in pain research Pain 66 1996 239 246
27. M. Woodward Epidemiology: Design and Data Analysis 2nd edition 2005 Chapman and Hall/CRC Press Boca Raton, FL
28. M. Egger, G. Davey Smith, M. Schneider Bias in meta-analysis detected by a simple, graphical test BMJ 315 1997 629 634
29. M. Barbir, B. Hunt, S. Kushwaha Maxepa versus Bezafibrate in hyperlipidemic cardiac transplant recipients Am J Cardiol 70 1992 1596 1601
30. R. Bruce, A. Daniels, T. Cundy Renal function changes in diabetic nephropathy induced by bezafibrate Nephron 73 1996 490
31. O. Samuelsson, P.O. Attman, C. Knight-Gibson Effect of gemfibrozil on lipoprotein abnormalities in chronic renal insufficiency: a controlled study in human chronic renal disease Nephron 75 1997 286 294
32. A. Levin, L. Duncan, O. Djurdjev A randomized placebo-controlled double-blind trial of lipid-lowering strategies in patients with renal insufficiency: diet modification with or without fenofibrate Clin Nephrol 53 2000 140 146
33. J.C. Ansquer, C. Foucher, S. Rattier Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS) Am J Kidney Dis 45 2005 485 493
34. R. Ting, A. Keech, M.W. Donoghoe Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment Diabetes Care 35 2012 218 225
35. Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med;362:1563-74.
36. M. Tonelli, D. Collins, S. Robins Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency Kidney Int 66 2004 1123 1130
37. A. Keech, R.J. Simes, P. Barter Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial Lancet 366 2005 1849 1861
38. M. Tonelli, D. Collins, S. Robins Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease Am J Kidney Dis 44 2004 832 839
39. T. Quasching, M. Schomig, M. Keller Non-insulin-dependent diabetes mellitus and hypertriglyceridemia impair lipoprotein metablism in chronic hemodialysis patients J Am Soc Nephrol 10 1999 322 341
40. Kidney Disease Outcomes Quality Initiative (K/DOQI) Group K/DOQI clinical practice guidelines for managing dyslipidemia in chronic kidney disease Am J Kidney Dis 41 2003 S1 S237
41. E. Di Angelantonio, R. Chowdhury, N. Sarwar Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: prospective population based cohort study BMJ 341 2010 c4986
42. P.A. McCullough, A.B. Ahmed, M.T. Zughaib Treatment of hypertriglyceridemia with fibric Acid derivatives: impact on lipid subfractions and translation into a reduction in cardiovascular events Rev Cardiovasc Med 12 2011 173 185
43. J.C. Ansquer, R.N. Dalton, E. Causse Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people Am J Kidney Dis 51 2008 904 913
44. Y.L. Chen, C.Y. Hsu, W.C. Huang Fenofibrate reversibly increases serum creatinine level in chronic kidney disease patients by reducing glomerular filtration rate Acta Nephrologica 25 2011 1 4
45. Y.Y. Zhao, M.A. Weir, M. Manno New fibrate use and acute renal outcomes in elderly adults: a population-based study Ann Intern Med 156 2012 560 569
46. C. Hottelart, N. Esper, J.M. Achard Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency Nephrologie 20 1999 41 44
47. N. Broeders, C. Knoop, M. Antoine Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent? Nephrol Dial Transplant 15 2000 1993 1999
48. O. Devuyst, E. Goffin, Y. Pirson Creatinine rise after fibrate therapy in renal graft recipients Lancet 341 1993 840
49. J. Lipscombe, G.F. Lewis, D. Cattran Deterioration in renal function associated with fibrate therapy Clin Nephrol 55 2001 39 44
50. J.C. Mychaleckyj, T. Craven, U. Nayak Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants Diabetes Care 35 2012 1008 1014
51. K. Huwiler-Muntener, P. Juni, C. Junker, M. Egger Quality of reporting of randomized trials as a measure of methdologic quality JAMA 287 2002 2801 2804
52. D.A. Grimes, K.F. Schulz Blinding in randomised trials: hiding who got what Lancet 359 2002 696 700